Median Survival Rate Nearly Doubles Combining Inotuzumab with Chemotherapy

Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the
median survival rate nearly doubles combining Inotuzumab with chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.